Cell therapy with retrovirally transduced CD4+ T cells expressing a TCR specific-for-another-cancer-testis antigen, MAGE-A3, presented by HLA-DPB1*0401 also led to partial and complete response across several tumor types (Lu et al., 2017). Here, MAGEA3 is linked to neoplasm.